People fearful of taking part in vital clinical research

March 16, 2020

Fear is a major factor behind people's reluctance to take part in clinical research, such as trials to test new medicines and treatments, a global review has found.

In the UK, up to two thirds of trials currently fail to recruit their target number of participants for vital medical research.

The review, led by researchers at the University of York and Hull York Medical School, found that fear about testing new treatments and possible side effects was the most common reason given by patients for not wanting to participate.

The researchers looked at the results of more than 400 studies from around the world on the reasons behind recruitment to health and medical studies.

Concerns about privacy and confidentiality have also increased over the past decade, the study suggests.

Among black and minority ethnic (BAME) patients, distrust in research and medical professionals was also a common reason given for not wanting to participate.

The authors of the study are calling for the development of new schemes to increase participation in research, which address patient anxieties and motivations.

Lead author of the study, Dr Peter Knapp, from the Department of Health Sciences at the University of York and the Hull York Medical School, said: "Clinical trials are an essential part of developing new medicines and improving healthcare, but recruiting patients to take part is one of the biggest challenges researchers face.

"Our review highlights how people are held back from taking part in research by their fears surrounding losing control of the treatments they receive and worries about possible side effects.

"Lack of trust was also identified as a common barrier for minority ethic patients around the world - perhaps a legacy of major historical violations of ethical standards in cases like the Tuskegee syphilis experiment."

The study found that on the other hand trust in doctors and clinical staff; a desire to help others, and the potential for improvements in their own health, were key factors that motivated patients to get on board with research.

Common methods that are currently in place in the NHS to increase patient participation in research are designed to prompt memory and raise awareness via schemes including phone reminders and personalised letters addressed to patients. The research highlights how these methods may have missed the mark as neither of these factors were identified in the study as a barrier to participation.

Dr Knapp added: "Interestingly, we found quite a few gaps between the main reasons people gave for their reluctance to take part and the interventions currently in place in healthcare systems like the NHS to try to remove barriers to participation.

"There is a need for more research to identify effective recruitment strategies that draw on psychological theory and the facilitators and barriers identified in this overview.

"Feelings of fearfulness are clearly a key issue and so it would make sense to look at interventions focused on directly addressing patient concerns.

"A desire to help develop better healthcare for others also came up as a strong reason for taking part in research and trials, and so this - people's sense of altruism - is another possibility that could be explored as a way of appealing to people."

University of York

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to